ES2175166T3 - Derivados de ariletanolamina y su uso como agonistas de beta-adrenoceptores atipicos. - Google Patents

Derivados de ariletanolamina y su uso como agonistas de beta-adrenoceptores atipicos.

Info

Publication number
ES2175166T3
ES2175166T3 ES96943050T ES96943050T ES2175166T3 ES 2175166 T3 ES2175166 T3 ES 2175166T3 ES 96943050 T ES96943050 T ES 96943050T ES 96943050 T ES96943050 T ES 96943050T ES 2175166 T3 ES2175166 T3 ES 2175166T3
Authority
ES
Spain
Prior art keywords
alkyl
pct
trifluoromethyl
alkoxy
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96943050T
Other languages
English (en)
Inventor
Richard Howard Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2175166T3 publication Critical patent/ES2175166T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE FENETANOLAMINA DE FORMULA (I), DONDE R 1 REPRESENTA UN GRUPO ARILO OPCIONALMENTE SUSTITUIDO POR UNO O MAS SUSTITUYENTES SELECCIONADOS A PARTIR DE HALOGENO, HIDROXILO, ALCOXI C 1 C 6 , ALQUILO C 1 - C 6 , NITRO, CIANO, HIDROXIMETILO Y TRIFLUOROMETILO; R REPRESENTA HIDROGENO O ALQUILO C 1 - C S UB,6 ; R 3 REPRESENTA UN GRUPO (A), ESTANDO SUSTITUIDO EL CICLO POR ENTRE UNO Y CUATRO SUSTITUYENTES ADICIONALES SELECCIONADOS A PARTIR DE ALQUILO C 1 C 6 , HALOGENO, TRIFLU OROMETILO Y ALCOXI C 1 - C 6 ; O R 3 REPRESENTA UN GRUPO (B) EN EL QUE EL CICLO AROMATICO ESTA SUSTITUIDO OPCIONALMENTE POR ENTRE UNO Y TRES SUSTITUYENTES SELECCIONADOS A PARTIR DE ALQUILO C 1 - C 6 , HALOGENO, TRIFLUOROMETILO Y ALCOXI C 1 - C 6 ; R 4 REPRESENTA HIDROGENO O ALQUILO C 1 - C 6 ; R REPRESENTA ZCH 2 CO 2 H REPRESENTANDO Z UN ENLACE, O O; Y REPRESENTA (CH 2 ) N SIENDO N 1-3. ASIMISMO SE PRESENTAN LOS DERIVADOS FISIOLOGICAMENTE ACEPTABLES DE LOS MISMOS, PROCEDIMIENTOS DE PREPARACION DE LOS MISMOS Y SU UTILIZACION EN ALTERACIONES SUSCEPTIBLES DE MEJORA MEDIANTE UN AGONISTA DE ADRENOACEPTOR DE TIPO BETA ATIPICO.
ES96943050T 1995-12-08 1996-12-06 Derivados de ariletanolamina y su uso como agonistas de beta-adrenoceptores atipicos. Expired - Lifetime ES2175166T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9525177.3A GB9525177D0 (en) 1995-12-08 1995-12-08 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2175166T3 true ES2175166T3 (es) 2002-11-16

Family

ID=10785166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96943050T Expired - Lifetime ES2175166T3 (es) 1995-12-08 1996-12-06 Derivados de ariletanolamina y su uso como agonistas de beta-adrenoceptores atipicos.

Country Status (9)

Country Link
US (1) US6048872A (es)
EP (1) EP0865421B1 (es)
JP (1) JP2000506498A (es)
AT (1) ATE215064T1 (es)
AU (1) AU1191597A (es)
DE (1) DE69620222T2 (es)
ES (1) ES2175166T3 (es)
GB (1) GB9525177D0 (es)
WO (1) WO1997021665A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
GB0102407D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Process
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052127A1 (de) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154761A (en) * 1976-02-09 1979-05-15 Allen & Hanburys Limited Pharmacologically active compounds
GB1593651A (en) * 1977-02-03 1981-07-22 Allen & Hanburys Ltd Amides
DE3428526A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue aminoalkohole, verfahren zu deren herstellung sowie diese verbindung enthaltende arzneimittel
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
AU2737295A (en) * 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists

Also Published As

Publication number Publication date
DE69620222D1 (de) 2002-05-02
WO1997021665A1 (en) 1997-06-19
ATE215064T1 (de) 2002-04-15
US6048872A (en) 2000-04-11
GB9525177D0 (en) 1996-02-07
AU1191597A (en) 1997-07-03
DE69620222T2 (de) 2002-10-24
EP0865421A1 (en) 1998-09-23
JP2000506498A (ja) 2000-05-30
EP0865421B1 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
DK0687268T3 (da) Spiroazacykliske derivater som substans P-antagonister
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
ES2173480T3 (es) Preparacion de derivados de ciclohexeno carboxilato.
BR9610960A (pt) Derivados de 8-azabiciclo [3.2.1] oct -2- eno sua preparação e uso
YU40997A (sh) Novi oksadiazoli, postupci za njihovo pripremanje
MXPA02000973A (es) Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
BG102715A (bg) Нови производни на арилглицинамид, метод за получаването им и фармацевтични състави съдържащи, ги
SE9502921D0 (sv) New compounds
ES2175166T3 (es) Derivados de ariletanolamina y su uso como agonistas de beta-adrenoceptores atipicos.
ATE297903T1 (de) Substituierte phenyluracile
AR000813A1 (es) Procedimiento para la obtencion de n-aril y n-heteroarilhidroxilaminas
ES2181772T3 (es) Compuesto de eter, su utilizacion e intermediario para la obtencion de este compuesto.
DE69703796D1 (de) N-bis- oder n-tris-[(1,2-dicarboxy-ethoxy)-ethyl]-amin-derivate und herstellung und anwendung derselben
DE69102762D1 (de) Beta-phenylisoserinderivate, ihre herstellung und ihre anwendung.
UA41350C2 (uk) Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
ES2166026T3 (es) Derivados de 1,2,3-benzotiadiazol y su uso como microbicidas.
AR009732A1 (es) Bisindolilmaleimidas, proceso para su preparacion, su uso en la preparacion de medicamentos, una composicion farmaceutica que los contiene y compuestosintermediarios para su uso exclusivo en el mencionado proceso
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
FI965097A0 (fi) Substituoidut alkyylidiamiinijohdannaiset ja niiden käyttö takykiniini antagonisteina
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
DE69612413D1 (de) 1-(Hetero)Arylvinyl-5H-2,3-benzodiazepinderivative verwendbar zur Behandlung von Erkrankungen des Zentralnervensystems, sowie Benzopyrylium Intermediate zu ihrer Herstellung
ES2161892T3 (es) Derivados de indol como profarmacos de agonistas de los receptores afines a 5-ht1.
IT1286141B1 (it) Derivati diammidici dell'acido antranilico ad attivita' antigastrinica procedimento per la loro preparazione e loro uso farmaceutico.
ES8800177A1 (es) Procedimiento de produccion de derivados as-triazinos condensados

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 865421

Country of ref document: ES